Skip to main content

Advertisement

Fig. 2 | BMC Cancer

Fig. 2

From: A novel combined systemic inflammation-based score can predict survival of intermediate-to-advanced hepatocellular carcinoma patients undergoing transarterial chemoembolization

Fig. 2

The overall survival rates of the two groups according postoperative prognostic nutrition index. a the 1-, 3-, 5- year overall survival rates in group A are 49.7, 25.1 and 12.4%, respectively; b the 1-, 3-, 5- year overall survival rates in group dNLR < 1.7 are 69.0, 39.7 and 26.2%, respectively. And, the 1-, 3-, 5-year overall survival rates in group dNLR ≥1.7 are 39.2, 17.1 and 6.0% respectively (P < 0.001); c the 1-, 3-, 5- year overall survival rates in group PNI < 46 are 42.8, 19.3 and 8.2%, respectively. And, the 1-, 3-, 5-year overall survival rates in group PNI ≥ 46 are 59.0, 32.6 and 17.9% respectively (P < 0.001); d the 1-, 3-, 5- year overall survival rates in group dNLR-PNI 0 are 71.7, 44.5 and 32.9%, respectively. And, the 1-, 3-, 5-year overall survival rates in group dNLR-PNI 1 are 55.3, 27.0 and 12.4% respectively. And, the 1-, 3-, 5-year overall survival rates in group dNLR-PNI 2 are 34.1, 13.8 and 4.6% respectively (P < 0.001)

Back to article page